About protagenic therapeutics - PTIX
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.
PTIX At a Glance
Protagenic Therapeutics, Inc.
149 Fifth Avenue
New York, New York 10010
| Phone | 1-212-994-8200 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -5,525,344.00 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PTIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.502 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.10 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PTIX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,841,781.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PTIX Liquidity
| Current Ratio | 1.997 |
| Quick Ratio | 1.997 |
| Cash Ratio | 1.95 |
PTIX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -175.986 |
| Return on Equity | -236.062 |
| Return on Total Capital | -545.361 |
| Return on Invested Capital | -236.062 |
PTIX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |